This article is more than 5 years old. Information may no longer be current.
Targeted oncolytic poxvirus increased liver cancer survival rates
Click Here to Manage Email Alerts
SAN FRANCISCO — A high-dose targeted oncolytic poxvirus, dubbed JX-594, increased survival rates in patients with advanced, previously treated hepatocellular carcinonma, according to phase 2 trial results presented during the Annual Meeting of the American Association for the Study of Liver Diseases.
For the study, researchers assigned patients to either a high-dose or low-dose group.
Results indicated that the survival rate among the low-dose group was 6.7 months vs. 13.8 months among those assigned the high-dose regimen, the researchers wrote.
At week 8, disease stabilization was observed in 52% of patients and a necrotic response in 54% of patients.
The researchers said their findings justify randomized controlled trials comparing JX-594 with first line standard of care and best supportive care in patients with no response to sorafenib (Nexavar, Bayer).